Drug intelligence / Profile preview

SUPREP mini S

Development stage: Unknown
Lead developer: Taejoon Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

**SUPREP mini S** is an oral fixed-dose bowel-cleansing preparation developed by Taejoon for colonoscopy and colonic X-ray preparation. It is an upgraded mini oral sulfate tablet product corresponding to CTP-0302 and combines anhydrous sodium sulfate, potassium sulfate, sodium chloride, potassium chloride, and simethicone. The sulfate salts act as poorly absorbed osmotic agents that retain water in the intestinal lumen and induce catharsis, while simethicone reduces foam and residual bubbles to improve mucosal visualization during colonoscopy. ([taejoon.co.kr](https://www.taejoon.co.kr/en/contents/poduct/informationView.do?mprSeq=303))

Brand names: SUPREP mini S
Other names: mini S-oral sulfate tabletmini S-OST

Targets

CTPS1 (Cytidine triphosphate synthase 1)

Beyond the preview

Go deeper on SUPREP mini S.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SUPREP mini S.

Explore the full profile